Market Closed -
Toronto S.E.
21:00:00 10/05/2024 BST
|
5-day change
|
1st Jan Change
|
1.59
CAD
|
-5.92%
|
|
-0.62%
|
-11.17%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
162.1
|
130.8
|
96.3
|
131
|
132.3
|
119.9
|
-
|
-
|
Enterprise Value (EV)
1 |
162.1
|
130.8
|
96.3
|
131
|
132.3
|
119.9
|
119.9
|
119.9
|
P/E ratio
|
-4.1
x
|
-5.39
x
|
-3.57
x
|
-5.16
x
|
-4.37
x
|
-3.68
x
|
-4.21
x
|
265
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
99.9
x
|
12
x
|
2.7
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
99.9
x
|
12
x
|
2.7
x
|
EV / EBITDA
|
-7.88
x
|
-5.23
x
|
-3.69
x
|
-4.94
x
|
-3.96
x
|
-2.86
x
|
-2.1
x
|
-1.36
x
|
EV / FCF
|
-
|
-5.92
x
|
-4.24
x
|
-5.6
x
|
-4.65
x
|
-2.04
x
|
-1.92
x
|
-1.53
x
|
FCF Yield
|
-
|
-16.9%
|
-23.6%
|
-17.9%
|
-21.5%
|
-49.1%
|
-52.2%
|
-65.2%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
26,358
|
43,319
|
55,027
|
59,029
|
73,914
|
75,420
|
-
|
-
|
Reference price
2 |
6.150
|
3.020
|
1.750
|
2.220
|
1.790
|
1.590
|
1.590
|
1.590
|
Announcement Date
|
05/03/20
|
05/03/21
|
03/03/22
|
03/03/23
|
07/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
1.2
|
10.01
|
44.39
|
EBITDA
1 |
-20.57
|
-25.01
|
-26.1
|
-26.53
|
-33.39
|
-41.95
|
-57.1
|
-88.2
|
EBIT
1 |
-20.69
|
-26.12
|
-26.23
|
-26.92
|
-33.79
|
-37.18
|
-39.07
|
-29.25
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-3,098.43%
|
-390.11%
|
-65.9%
|
Earnings before Tax (EBT)
1 |
-33.12
|
-22.51
|
-26.25
|
-24.75
|
-27.66
|
-34.68
|
-39.07
|
-29.23
|
Net income
1 |
-33.1
|
-22.51
|
-26.3
|
-24.84
|
-27.75
|
-34.66
|
-39.07
|
-29.23
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-2,888.64%
|
-390.11%
|
-65.85%
|
EPS
2 |
-1.500
|
-0.5600
|
-0.4900
|
-0.4300
|
-0.4100
|
-0.4315
|
-0.3776
|
0.006000
|
Free Cash Flow
1 |
-
|
-22.1
|
-22.72
|
-23.41
|
-28.46
|
-58.9
|
-62.55
|
-78.2
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-4,908.33%
|
-624.62%
|
-176.17%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
05/03/20
|
05/03/21
|
03/03/22
|
03/03/23
|
07/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1.5
|
-
|
EBITDA
1 |
-6.07
|
-7.432
|
-6.213
|
-5.949
|
-5.962
|
-8.409
|
-6.637
|
-7.064
|
-10.94
|
-8.742
|
-8.603
|
-9.9
|
-11
|
-14.1
|
-
|
EBIT
1 |
-6.155
|
-7.455
|
-6.31
|
-6.046
|
-6.06
|
-8.508
|
-6.734
|
-7.16
|
-11.05
|
-8.849
|
-8.726
|
-8.73
|
-9.224
|
-10.7
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-713.04%
|
-
|
Earnings before Tax (EBT)
1 |
-4.865
|
-7.709
|
-6.779
|
-5.07
|
-4.405
|
-8.498
|
-6.437
|
-7.394
|
-9.918
|
-3.906
|
-6.894
|
-8.505
|
-9.036
|
-9.13
|
-
|
Net income
1 |
-4.777
|
-7.751
|
-6.779
|
-5.095
|
-4.407
|
-8.554
|
-6.437
|
-7.441
|
-9.925
|
-3.949
|
-6.894
|
-8.505
|
-9.036
|
-9.13
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-608.66%
|
-
|
EPS
2 |
-0.0900
|
-0.1400
|
-0.1200
|
-0.0900
|
-0.0800
|
-0.1500
|
-0.1000
|
-0.1200
|
-0.1400
|
-0.0500
|
-0.0900
|
-0.1075
|
-0.1092
|
-0.1030
|
-0.1200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
05/11/21
|
03/03/22
|
05/05/22
|
11/08/22
|
07/11/22
|
03/03/23
|
05/05/23
|
14/08/23
|
03/11/23
|
07/03/24
|
09/05/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-22.1
|
-22.7
|
-23.4
|
-28.5
|
-58.9
|
-62.6
|
-78.2
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-0.5500
|
-0.4200
|
-0.4000
|
-0.4200
|
-0.4000
|
-
|
-
|
Capex
1 |
0.01
|
0.03
|
0.29
|
0.06
|
0.01
|
1
|
0.5
|
10
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
83.33%
|
4.99%
|
22.53%
|
Announcement Date
|
05/03/20
|
05/03/21
|
03/03/22
|
03/03/23
|
07/03/24
|
-
|
-
|
-
|
Last Close Price
1.59
CAD Average target price
6.625
CAD Spread / Average Target +316.67% Consensus |
1st Jan change
|
Capi.
|
---|
| -11.17% | 87.77M | | +17.96% | 44.96B | | +48.77% | 41.85B | | +1.17% | 42.65B | | -4.27% | 29.04B | | +11.42% | 26.08B | | -21.39% | 19.03B | | +4.86% | 12.75B | | +27.29% | 12.06B | | -3.50% | 11.75B |
Other Biotechnology & Medical Research
|